Doctors & patients are saying about ''...

" is a great web site for patients, that is unequaled by anything else out there."

Dr. Douglas L. Packer, MD, FHRS, Mayo Clinic, Rochester, MN

"Jill and I put you and your work in our prayers every night. What you do to help people through this [A-Fib] process is really incredible."

Jill and Steve Douglas, East Troy, WI 

“I really appreciate all the information on your website as it allows me to be a better informed patient and to know what questions to ask my EP. 

Faye Spencer, Boise, ID, April 2017

“I think your site has helped a lot of patients.”

Dr. Hugh G. Calkins, MD  Johns Hopkins,
Baltimore, MD

Doctors & patients are saying about 'Beat Your A-Fib'...

"If I had [your book] 10 years ago, it would have saved me 8 years of hell.”

Roy Salmon, Patient, A-Fib Free,
Adelaide, Australia

"This book is incredibly complete and easy-to-understand for anybody. I certainly recommend it for patients who want to know more about atrial fibrillation than what they will learn from doctors...."

Pierre Jaïs, M.D. Professor of Cardiology, Haut-Lévêque Hospital, Bordeaux, France

"Dear Steve, I saw a patient this morning with your book [in hand] and highlights throughout. She loves it and finds it very useful to help her in dealing with atrial fibrillation."

Dr. Wilber Su,
Cavanaugh Heart Center, 
Phoenix, AZ

"...masterful. You managed to combine an encyclopedic compilation of information with the simplicity of presentation that enhances the delivery of the information to the reader. This is not an easy thing to do, but you have been very, very successful at it."

Ira David Levin, heart patient, 
Rome, Italy

"Within the pages of Beat Your A-Fib, Dr. Steve Ryan, PhD, provides a comprehensive guide for persons seeking to find a cure for their Atrial Fibrillation."

Walter Kerwin, MD, Cedars-Sinai Medical Center, Los Angeles, CA

A-Fib Patients: Vazalore to Replace Aspirin

In 2014, Aspirin was removed from the AHA/ACC/HRS Guidelines for the Management of Patients with Atrial Fibrillation. (See my 2020 Update: Aspirin No Longer Recommended as First-Line Therapy for Stroke.)

There hasn’t been innovation in the mechanism of Aspirin delivery in over 50 years.

Not only is Aspirin proved relatively ineffective as an anticoagulant but it causes increased risk of gastrointestinal (GI) bleeding, ulcers, nose bleeds, wet macular degeneration, and hemorrhagic stroke.

For secondary prevention patients (after a heart attack), nearly 25% with a history of GI issues reported discontinuing aspirin against medical advice because of “stomach issues”.

Vazalore: Delivers Aspirin in a New Form

Vazalore Aspirin Therapy from PLx Pharma

In March 2021, the U.S. FDA approved the medication, Vazalore (PLx Pharma), a capsule containing aspirin and protective fatty substances called liposomes.

As liquid-filled capsules, Vazalore delivers Aspirin differently. The special complex inside the capsule allows for targeted release of aspirin, limiting its direct contact with the stomach.

Vazalore works four times faster than aspirin, with 71% less injury. It’s absorbed five times better than aspirin. It comes in low-dose (81 mg) and full-strength (325 mg) versions.

Aspirin Continues as “Secondary” Prevention

“Secondary prevention” refers to those who have already had a stroke or heart attack; the goal is to prevent another.

While no longer recommended as an anticoagulant for Atrial Fibrillation patients, Aspirin still has a roll to play in cardiac health.

Aspirin is recommended for a “secondary” prevention of recurrence of a heart attack. It significantly reduces the risk for a second heart attack or stroke. (Translation: If you’ve already had a heart attack or stroke, you may be on traditional Aspirin to prevent a second event.)

Editor’s Comments

Editor's Comments about Cecelia's A-Fib story

It’s too early to tell how Vazalore compares to the use of DOACs (Direct-Acting Oral Anticoagulants).
But for those who have to take Aspirin (such as people with stents), Vazalore seems like a major game changer and medical breakthrough. It’s a way to get the benefits of aspirin without the bad side effects such as GI bleeding, ulcers, etc.
Now that Vazalore is FDA approved, let’s wait and see how it performs in practice as compared to clinical trials.
Are you on Vazalore? If you have been taking Vazalore for your Atrial Fibrillation, would you share your impressions? Email me and let me know about your experience.
• PLx Pharma Receives FDA Approval of SNDAs for Both VAZALORE 325 mg and 81 mg. March 1, 2021. PLx Pharma, Inc. press release.

• Cryer, Byron. New form of aspirin is easier on the stomach. Bottom Line Personal. Volume 42, Number 21, November 1, 2021. p. 11.

• Moberg C, Naesdal J, Svedberg LE, Duchateau D, Harte N. Impact of gastrointestinal problems on adherence to low-dose acetylsalicylic acid: a quantitative study in patients with cardiovascular risk. Patient. 2011;4(2):103-113.


Related Posts

Follow Us
facebook - A-Fib.comtwitter - A-Fib.comlinkedin - A-Fib.compinterest - A-Fib.comYouTube: A-Fib Can be Cured! -

We Need You Help be self-supporting-Use our link to Amazon is a
501(c)(3) Nonprofit

Your support is needed. Every donation helps, even just $1.00. top rated by since 2014 

Home | The A-Fib Coach | Help Support | A-Fib News Archive | Tell Us What You think | Press Room | GuideStar Seal | HON certification | Disclosures | Terms of Use | Privacy Policy